Navigation Links
Novartis Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing's Disease, a Debilitating Hormonal Disorder
Date:9/21/2010

ebilitating disease," said William H. Ludlam, MD, PhD, Director, Seattle Pituitary Center at the Swedish Neuroscience Institute in Seattle, WA.  "The results of this study suggest that pasireotide may help patients achieve biochemical control of their Cushing's disease and its symptoms by directly targeting the pituitary tumor that triggers excess cortisol production."

PASPORT-CUSHINGS (PASireotide clinical trial PORTfolio - CUSHING'S disease) is the largest randomized study to evaluate a medical therapy in patients with Cushing's disease(1). The trial is part of a large-scale global clinical development program to assess the efficacy and safety of SOM230 in a range of pituitary and neuroendocrine tumors(6).

"Positive results from this trial bring us one step closer to providing physicians with a new treatment option to offer people living with the physically and emotionally debilitating symptoms associated with Cushing's disease," said Herve Hoppenot, President, Novartis Oncology.

These data will form the basis for the first regulatory filing of SOM230 planned this year. SOM230 has orphan drug designation for Cushing's disease in the US and Europe(7),(8). In the US, orphan drugs are those developed to treat diseases affecting fewer than 200,000 people(9). In Europe, orphan drugs are those developed to treat conditions affecting fewer than five in 10,000 people(8).

Study detailsPASPORT-CUSHINGS is a prospective Phase III study of 162 patients conducted at 68 sites in 18 countries. The study evaluated the efficacy and safety of SOM230 in patients with persistent or recurrent Cushing's disease, as well as in patients with newly diagnosed Cushing's disease who are not candidates for surgery(1),(10).

Patients with primarily moderate to severe hypercortisolism were randomized to receive SOM230 subcutaneous (sc) injection in doses of 600ug (n=82) or 900ug (n=80) twice daily. The primary endpoint was the proportion of patients who
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- Commonwealth Cornerstone Group (CCG) today announced the completion of an ... help fund the expansion and consolidation of healthcare services provided ... . PHN is the largest federally qualified ... is the largest employer in Sharon,s ... Currently, PHN Sharon offers scattered services out of ...
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission ... ResMed (RMD) against BMC Medical. In a notice issued on ... found that ResMed,s patent on its humidifier was invalid. ... a "monumental win". "We are very excited with the ITC,s ... position that we have taken since the very beginning on ...
(Date:12/24/2014)... and LONDON , December 24, ... industry are expected to grow at an average rate ... of value and volume. Hip, knee and spine surgeries ... while in emerging economies they have a lower penetration. ... challenging the use of composites. Non-metallic orthopedic devices have ...
Breaking Medicine Technology:Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... International, a leading Clinical Research Organization, will host an ... development on 24 August 2010 at 11:30 am (EDT). ... Scientific Affairs unit, will be the presenter. ... the expensive failures that pharmaceutical companies experience during late-stage ...
... Bulletin Board: WGBS ), a leading developer of ... three and six months ended June 30, 2010.   ... 2010 grew to $432,000 compared to $69,000 for the second ... ended June 30, 2010 grew to $822,000 compared to $111,000 ...
Cached Medicine Technology:PRA International Hosts Audio Conference on CV Drug Development 2WaferGen Reports Second Quarter 2010 Financial Results 2WaferGen Reports Second Quarter 2010 Financial Results 3WaferGen Reports Second Quarter 2010 Financial Results 4WaferGen Reports Second Quarter 2010 Financial Results 5WaferGen Reports Second Quarter 2010 Financial Results 6WaferGen Reports Second Quarter 2010 Financial Results 7
(Date:12/25/2014)... (PRWEB) December 26, 2014 The report ... 2023” focuses on the current treatment landscape, unmet needs, ... market. TS-1 is an anti-cancer drug which is typically ... and is also used for treating gastric cancer and ... otastat potassium. The drug was first approved in 1999 ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 The short film ... was created in honor of a true 9/11 hero, Welles ... film festivals including the 24 hours of Nuremberg International Short ... Bangladesh. , Actress, screenwriter and director Luciana Lagana ... this film together with her husband, Gregory Graham ...
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional shopping ... of the models at LunaDress.co.uk come with big discounts, up to ... veil can turn out to be a most exciting memory and ... always bring surprise to a wedding. On the updated fashion blog, ... veils for a big day . , Going out with friends ...
(Date:12/25/2014)... Dennis Thompson HealthDay ... Researchers could be closing in on a "fountain of youth" ... the health of older adults, a new study suggests. ... given a drug that targets a genetic signaling pathway linked ... Novartis report. The experimental medication, a version ...
(Date:12/25/2014)... North Carolina (PRWEB) December 25, 2014 ... North Carolina Retirement Community, recently showed their generous ... girls of the Catawba County Parenting Network- Grandparents ... the 10 children gathered around the largest Christmas ... to open presents purchased by residents of the ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Retirement Community Residents Make Impact During Holiday Season 2
... phone use does not appear to increase the risk ... study by University of Manchester scientists suggests. The ... of National Statistics to look at trends in rates ... and 2007. The study, published in the journal ...
... at The Wistar Institute and the University of Pennsylvania ... that could provide physicians with the first reliable blood ... in the February 16 issue of the Journal ... related small-scale study of clinical samples, published recently in ...
... or simultaneous total knee replacement (TKR) was associated with ... revision knee operations within one year after surgery, compared ... However, simultaneous replacement was associated with a moderately higher ... to a study presented today at the 2011 Annual ...
... February issue of the Journal of the American ... manufacturers to navigate the unique and increasingly complex U.S. ... Devices: From Concept to Adoption," identifies and addresses the ... distinct clinical evidence needs for each phase. This ...
... advancing the diversity of doctoral-level chemists entering the workforce, ... the Advancement of Science (AAAS) will be bestowed upon ... the Chancellor,s Eminent Professor of Chemistry at the University ... the William R. Kenan, Jr. Distinguished Professor of Chemical ...
... more likely to experience health problems, including asthma and accidents, ... research from North Carolina State University. "I don,t think ... decision to work or not work," says Dr. Melinda Morrill, ... of the study. "But, it is important that we are ...
Cached Medicine News:Health News:Cell-phone use not related to increased brain cancer risk 2Health News:Biomarker discovery may lead to reliable blood test for ectopic pregnancy 2Health News:Biomarker discovery may lead to reliable blood test for ectopic pregnancy 3Health News:2 knee replacements may be better than 1 2Health News:Researchers develop outline that may help weigh benefits of new imaging technologies 2Health News:2010 AAAS Mentor Award goes to Dr. Joseph M. DeSimone of the University of North Carolina at Chapel Hill, and North Carolina State University 2Health News:2010 AAAS Mentor Award goes to Dr. Joseph M. DeSimone of the University of North Carolina at Chapel Hill, and North Carolina State University 3Health News:2010 AAAS Mentor Award goes to Dr. Joseph M. DeSimone of the University of North Carolina at Chapel Hill, and North Carolina State University 4Health News:Children of working moms face more health problems 2
... The HM 560 Cryo-Star - ... have been incorporated which offer the ... electronic, optionally motorized cryostat with retraction ... for independent specimen and knife cooling. ...
... represents a new tissue infiltration instrument, which ... masterly way. The robust caroussel design is ... space. The instrument includes either 10 reagent ... and 3 paraffin containers. Up to 10 ...
... a power assisted microtome combines the advantages ... horizontal movements are proportionally related to the ... Duplicate controls provide for convenient operation with ... operating levers and handles may be positioned ...
... microtome comes in two different versions - ... All RM2125 versions are now equipped with ... precision micrometer feeding system. The Leica RM2125 ... and specimen retraction as additional features. The ...
Medicine Products: